Real-World Analysis of Post-Progression Treatment Patterns and Outcomes for EGFR Mutation-Positive Patients Treated with First-Line Osimertinib
Current Oncology · 2024
DOI: 10.3390/curroncol31050182 ↗Kurz gefasst
Fachartikel in der Zeitschrift Current Oncology, 2024. Verfasst von Amanda Jane Williams Gibson und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, Cumming School of Medicine, University of Calgary, 3330 Hospital Drive NW, Calgary, AB T2N 4N1, Canada. Hauptthemen laut MEDLINE: Aniline Compounds, Acrylamides, ErbB Receptors, Mutation. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Philanthropic donation to the Glans-Look Lung Cancer Research Database, Glans-Look Lung Cancer Research.
Abstract (Originalsprache)
Introduction
The use of osimertinib in the first-line (1L) setting is an effective treatment option for sensitizing EGFR-mutations (EGFRm+) and has significantly altered the standard of care practice for EGFRm+ disease in Canada. Unfortunately, acquired resistance to osimertinib is almost universal, and outcomes are disparate. Post-progression treatment patterns and the outcome of real-world Canadian EGFRm+ patients receiving 1L osimertinib were the focus of this retrospective review.
Methods
The Glans-Look Lung Cancer Research database was used to identify and collect demographic, clinical, treatment, and outcome data on EGFRm+ patients who received 1L osimertinib in the Canadian province of Alberta between 2018 and 2022.
Results
A total of 150 patients receiving 1L osimertinib were identified. In total, 86 developed progressive disease, with 56 (65%) continuing systemic therapy, 73% continuing osimertinib, and 27% switching to second-line (2L) systemic therapy. Patients were similar both in clinical characteristics at 1L osimertinib initiation and patterns of treatment failure at progression; those continuing 1L osimertinib post-progression had a longer time to progression (13.5 vs. 8.8 months, p = 0.05) and subsequent post-osimertinib initiation survival (34.7 vs. 22.8 months, p = 0.11).
Conclusions
The continuation of osimertinib post-progression is an effective disease management strategy for select real-world EGFRm+ patients, providing continued clinical benefit, potentially due to different underlying disease pathogenesis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Oncology, Cumming School of Medicine, University of Calgary, 3330 Hospital Drive NW, Calgary, AB T2N 4N1, Canada.
- Alberta Precision Laboratories, Molecular Pathology Laboratory, 3535 Research Road NW, Calgary, AB T2L 2K8, Canada.
- Division of Medical Oncology, Tom Baker Cancer Centre, Alberta Health Services, 1331 29 St NW, Calgary, AB T2N 4N2, Canada.
ORCID-Profile: Amanda Jane Williams Gibson, Vishal Navani
Förderung
- Philanthropic donation to the Glans-Look Lung Cancer Research Database
- Glans-Look Lung Cancer Research
Zitieren
APA
Gibson, A. J. W., Dean, M. L., Litt, I., Box, A., Cheung, W. Y., & Navani, V. (2024). Real-World Analysis of Post-Progression Treatment Patterns and Outcomes for EGFR Mutation-Positive Patients Treated with First-Line Osimertinib. Current Oncology. https://doi.org/10.3390/curroncol31050182
Vancouver
Gibson AJW, Dean ML, Litt I, Box A, Cheung WY, Navani V. Real-World Analysis of Post-Progression Treatment Patterns and Outcomes for EGFR Mutation-Positive Patients Treated with First-Line Osimertinib. Current Oncology. 2024. doi:10.3390/curroncol31050182
BibTeX
@article{Gibson2024,
author = {Gibson, Amanda Jane Williams and Dean, Michelle Liane and Litt, Ishjot and Box, Adrian and Cheung, Winson Y and Navani, Vishal},
title = {Real-World Analysis of Post-Progression Treatment Patterns and Outcomes for EGFR Mutation-Positive Patients Treated with First-Line Osimertinib},
journal = {Current Oncology},
year = {2024},
doi = {10.3390/curroncol31050182}
}
EUVIMED